ApoE Primary Antibody
|Aliases||AD2; LPG; LDLCQ5; MGC1571|
|Formulation||Ascitic fluid containing 0.03% sodium azide.|
|Immunogen||Purified recombinant fragment of human ApoE expressed in E. Coli. |
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
|References (references)||1. Arch Dermatol Res. 2009 Jul;301(6):405-10. |
2. Pharmacogenomics J. 2009 Aug;9(4):248-57.